http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
의인성 망막열공 : 발생 빈도 및 수술성적 Incidence and Surgical Results
김용백,강재훈,서병로,민욱기 충남대학교 의과대학 지역사회의학연구소 1990 충남의대잡지 Vol.17 No.2
We reviewed 61 consecutive eyes recently subjected to vitrectomy to determine the incidence and outcome of iatrogenic retinal tears. Iatrogenic retinal tears occurred in 14 eyes(22%). 14 eyes had 22 iatrogenic retinal tears. The incidence of iatrogenic peripheral tears was 6% and of posterior tears was 16%. Two thirds of tears occurred in the inferior quadrants. 43% of iatrogenic retinal tears occurred in patients with proliferative diabetic retinopathy. The overall anatomic success was achieved in 10 eyes(71%), 9 eyes of which were successfully treated with the initial operations. With a combination of intraocular gas tamponade, laser photocoagulation, cryopexy, or scleral bucking, 71% of iatrogenic retinal tears were successfully treated.
이진수,강병욱 東新大學校 工業技術硏究所 2000 工業技術硏究 Vol.6 No.-
The purpose of the present study is to examine geotechnical properties of slaking material, especially its slaking characteristics, crushing characteristics and shear behavior characteristics caused by an alternation of dryness and wetness. The data presented on this paper are based largely on such experiments as x-ray test, cation exchange capacity test, slaking test, crushing test, direct shear test and residual shear box test. The experiments were carried out with the following results: Slaking rate and Crushing rate rise 1 to 1.5% with the alternation of dryness and wetness. Friction angle φ in natural state is about 40° , and cohesion c 0.33 kg/cm². With the alternation repeated, the former shows relatively narrow range of variation while the latter gradually decrease to 0.12 kg/cm² after five rounds of slaking. As to the result of residual shear box test, the maximum strength is equal to that of direct shear test. In case of its residual strength, however, shows wide range of variation, 28.61° to 38.16° and Cr gradually decrease from 0.16 kg/cm² to 0.08 kg/cm².
Kang, Byung Woog,Kim, Jong Gwang,Chae, Yee Soo,Lee, Yoo Jin,Lee, Soo Jung,Moon, Joon Ho,Sohn, Sang Kyun,Jung, Min Kyu,Jeon, Seong Woo,Jang, Yun-Jin,Seo, Jongduk,Lee, Yong Hyun,Kwon, Ohkyung,Chung, Ho M. Nijhoff ; Kluwer Academic Publishers 2012 Investigational new drugs Vol.30 No.4
<P>The feasibility of a 3-week combination of S-1 and cisplatin as an adjuvant chemotherapy for patients with curatively resected gastric cancer was investigated.</P>
Kang, Byung Woog,Jeong, Ji Yun,Chae, Yee Soo,Lee, Soo Jung,Lee, Yoo Jin,Choi, Jun Young,Lee, In-Kyu,Jeon, Seong Woo,Bae, Han Ik,Lee, Da Keun,Kwon, Oh-Kyoung,Chung, Ho Young,Yu, Wansik,Kim, Jong Gwang Springer 2012 Cancer chemotherapy and pharmacology Vol.70 No.5
<P>Purpose The present study analyzed the expression of phosphorylated AMP-activated protein kinase (pAMPK), Fyn kinase, and pyruvate dehydrogenase kinase-1 (PDK-1) and their impact on the survival of patients with resected gastric cancer who received cisplatin-based adjuvant chemotherapy. Patients and methods Korean patients with stage II-IV (M0) gastric adenocarcinoma who underwent a gastrectomy with D2 lymph node resection and received a combination regimen of cisplatin and S-1 were enrolled. Immunohistochemistry was carried out to determine the expression of pAMPK, Fyn kinase, and PDK-1 in operative specimens of gastric cancer. The expression was divided into two groups according to the intensity score (negative: 0 or 1+ and positive: 2+ or 3+). Results From January 2006 to July 2010, 73 tumor samples obtained from 74 patients were analyzed. Forty patients were included in the pAMPK-positive group, while 33 patients were included in the pAMPK-negative group. Meanwhile, positive Fyn kinase expression was observed in only 10 patients (13.7 %), and there was no or very weak PDK-1 staining. The clinicopathologic characteristics were similar between the two groups according to the expression of pAMPK. With a median follow-up duration of 26.5 months (2.6-73.2), the estimated 3-year relapse-free survival (RFS) and overall survival rates were 55.0 and 78.4 %, respectively. In a multivariate analysis adjusted for age, sex, Lauren classification, and stage, the pAMPK-negative group was significantly associated with improved RFS (Hazard ratio = 0.459, 95 % CI 0.109-0.711, P = 0.043). Conclusion A low expression of pAMPK was found to be correlated with better RFS in patients with resected gastric cancer treated with adjuvant cisplatin-based chemotherapy.</P>
Lee, Soo Jung,Kang, Byung Woog,Moon, Joon Ho,Chae, Yee Soo,Kim, Jong Gwang,Jung, Joo Seop,Cho, Goon-Jae,Jo, Deog-Yeon,Kim, Yeo Kyeoung,Kim, Hyeoung Joon,Ryoo, Hun-Mo,Eom, Hyeon Seok,Le, Sang Min,Joo, S. Karger AG 2012 Acta haematologica Vol.127 No.2
<P>Abstract</P><P>This study compared the results of allogeneic peripheral blood stem cell transplantation (PBSCT) from unrelated and related donors in 142 consecutive patients with acute myeloid leukemia (AML). The cumulative incidence of acute graft-versus-host disease (GVHD) was 37.6% in the related PBSCT group and 53.7% in the unrelated PBSCT group. The cumulative incidence of extensive chronic GVHD was also higher in the unrelated PBSCT group (19.5%) than in the related PBSCT group (8.9%). The overall survival rate at 4 years was 62.4 ± 5.4 and 53.8 ± 1.2% (p = 0.535) in the related and unrelated PBSCT group, respectively. In a multivariate analysis, unrelated PBSCT was identified as a risk factor for the development of extensive chronic GVHD (hazard ratio = 3.019, p = 0.027). Unfavorable cytogenetics and the disease status at the time of transplantation were found to be related to overall survival. In the case of high-risk AML, the survival rate and relapse incidence were significantly better in the matched unrelated PBSCT group (p = 0.047 and 0.039, respectively). In conclusion, the allogeneic PBSCT outcomes for AML were comparable in the matched related and matched unrelated groups. Nonetheless, for high-risk AML patients, matched unrelated PBSCT was found to be preferable to matched related PBSCT.</P><P>Copyright © 2011 S. Karger AG, Basel</P>
Lee, Soo Jung,Kang, Byung Woog,Chae, Yee Soo,Kim, Hye Jin,Park, Su Yeon,Park, Jun Seok,Choi, Gyu Seog,Jeon, Hyo-Sung,Lee, Won Kee,Kim, Jong Gwang Raven Press 2014 Annals of Surgical Oncology Vol.21 No.suppl4
<P>Assuming an association between cancer and metabolism, oncogene-directed metabolic reprogramming in cancer has revealed new target strategies. For example, the LKB1-AMPK-mTOR signaling pathway genes are already known to alter the cell metabolism and to play a critical role in the malignant behavior of cancer. Accordingly, based on the assumption that genetic variations in the LKB1-AMPK-mTOR signaling pathway can change the intracellular signal in terms of metabolic reprogramming, the present study analyzed 18 single nucleotide polymorphisms (SNPs) of the STK11, PRKAA1, TSC1/2, and mTOR genes and their impact on the survival of patients with colorectal cancer.</P>
( In Hee Lee ),( Byung Woog Kang ),( Jong Gwang Kim ),( Woo Kyun Bae ),( Myung Seo Ki ),( Inkeun Park ),( Jae-cheol Jo ),( Jin Young Kim ),( Sung Ae Koh ),( Kyung Hee Lee ),( Yoon Young Cho ),( Hun Mo 대한내과학회 2020 The Korean Journal of Internal Medicine Vol.35 No.1
Background/Aims: For metastatic renal cell carcinoma (RCC), various prognostic scoring systems have been developed. However, owing to the low prevalence of non-clear cell RCC, the three most commonly used tools were mainly developed based on patients with clear cell histology. Accordingly, this study applied three prognostic models to Korean non-clear cell RCC patients treated with first-line temsirolimus. Methods: This study analyzed data for 74 patients with non-clear cell RCC who were treated with temsirolimus as the first-line therapy at eight medical centers between 2011 and 2016. The receiver-operating characteristic (ROC) curves for the different prognostic models were analyzed. Results: Twenty-seven (36.5%), 24 (32.4%), and 44 patients (59.5%) were assigned to the poor prognosis groups of the Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic RCC Database Consortium (IMDC), and Advanced Renal Cell Carcinoma (ARCC) risk stratification models, respectively. All three prognostic models reliably discriminated the risk groups to predict progression-free survival and overall survival (p < 0.001). The area under the ROC curve (AUC) for progression and survival was highest for the ARCC model (0.777; 0.734), followed by the IMDC (0.756; 0.724) and the MSKCC (0.742; 0.712) models. Furthermore, the sensitivity and specificity for predicting progression were highest with the ARCC model (sensitivity 63.6%, specificity 85.7%), followed by the MSKCC (sensitivity 58.2%, specificity 86.5%) and the IMDC models (sensitivity 56.4%, specificity 85.7%). Conclusions: All three prognostic models accurately predicted the survival of the non-clear cell RCC patients treated with temsirolimus as the first-line therapy. Furthermore, the ARCC risk model performed better than the other risk models in predicting survival.
박인근 ( Inkeun Park ),강병욱 ( Byung Woog Kang ),고수진 ( Su-jin Koh ),김경하 ( Kyoung Ha Kim ),김세현 ( Se Hyun Kim ),김찬규 ( Chan Kyu Kim ),김호영 ( Ho Young Kim ),박권오 ( Kwonoh Park ),박세훈 ( Se Hoon Park ),오성용 ( Sung Y 대한내과학회 2017 대한내과학회지 Vol.92 No.2
The management of advanced prostate cancer has evolved rapidly. Androgen deprivation therapy, via surgical or medical castration, is the first-line therapy for hormone-naive metastatic prostate cancer. For approximately a decade, docetaxel-based chemotherapy was the only approved agent to show a survival benefit for castration-resistant prostate cancer. However, over the last 5 years, significant advances in the field have led to the approval of several new agents with different mechanisms of action, such as the new androgen pathway inhibitors abiraterone and enzalutamide, a new cytotoxic agent, cabazitaxel, and new bone-seeking agents such as radium-223, which have all been associated with improved quality of life and pain palliation and an increase in survival. However, there has been no Korean treatment guideline for metastatic prostate cancer which is developed based on thorough search for relevant articles, including recently developed agents, and adequate review and assessment of evidences, and thus, a guideline adequate for domestic circumstance is eagerly needed. Experts from the Genitourinary Oncology Committee of the Korea Cancer Study Group developed clinical recommendations for the treatment of metastatic prostate cancer based on 19 key questions. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines. These are the first Korean treatment guidelines developed specifically for metastatic prostate cancer. (Korean J Med 2017;92:124-141)